Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.33 |
| ▸ | ITGAL | P20701 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10078330 | 1.00 | LMNA (0.50) | LMNACA12CA1CA2CA3 | |
| SCHEMBL16093503 | 0.88 | ACE (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4519294 | 0.84 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12052203 | 0.81 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10029734 | 0.81 | TSHR (0.41) | ACEDPP4PTPN1MAPT | |
| SCHEMBL28241899 | 0.79 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28241900 | 0.79 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| SCHEMBL15190077 | 0.79 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10078336 | 0.79 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10078325 | 0.78 | LMNA (0.50) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1993998-B1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA SA (BE) | 2013-08-21 | — | — | EP | claimed |
| US-12203938-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20220357331-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2022-11-10 | — | — | US | disclosed |
| US-11231424-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20200240991-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2020-07-30 | — | — | US | disclosed |
| US-20150044693-A1 | Levetiracetam Immunoassays | ARK DIAGNOSTICS, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8841136-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-1993998-B1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA SA (BE) | 2013-08-21 | — | — | EP | disclosed |
| EP-2349335-B1 | LEVETIRACETAM IMMUNOASSAYS | ARK DIAGNOSTICS INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20120190047-A1 | Levetiracetam Immunoassays | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2012-07-26 | — | — | US | disclosed |
| US-8168756-B2 | Levetiracetam immunoassays | ARK DIAGNOSTICS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8076493-B2 | 3-carboxy-2-oxo-1-pyrrolidine derivatives and their uses | UCB PHARMA, S.A. (BE) | 2011-12-13 | — | — | US | disclosed |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT | 2010-07-08 | — | — | US | disclosed |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | UCB PHARMA, S.A. (BE) | 2009-01-08 | — | — | US | disclosed |
| EP-1993998-A1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB Pharma, S.A. (BE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007065634-A1 | 3-CARBOXY- 2-OXO-1 -PYRROLIDINE DERIVATIVES AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12203938-B2 | Levetiracetam immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20220357331-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20090012313-A1 | 3-Carboxy-2-Oxo-1-Pyrrolidine Derivatives and Their Uses | ALDH18A1, PYCR1, OPRD1 | LMNA 4658/4885CA12 1665/4885CA1 2436/4885 |
| US-20200240991-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20120190047-A1 | Levetiracetam Immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-11231424-B2 | Levetiracetam immunoassays | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
| US-20100173427-A1 | LEVETIRACETAM IMMUNOASSAYS | GABRG1, GABRA6, LY96 | LMNA 1758/4885CA12 727/4885CA1 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.